Contact information
Colleges
Bethan Psaila
MA; MBBS; MRCP; FRCPath; PhD
Associate Professor of Haematology
- Cancer Research UK Advanced Clinician Scientist
Using single-cell approaches to study normal and malignant megakaryocyte development and myeloproliferative neoplasms
I study megakaryocytes - large, rare cells found in the bone marrow that release blood platelets into the circulation and also produce many growth factors and other proteins that regulate blood cell development and the bone marrow microenvironment. My group applies state-of-the-art single-cell approaches to clarify the cellular pathways by which megakaryocytes arise from haematopoietic stem cells. This is important as in certain malignancies, such as erythro-megakaryocytic leukaemias and myeloproliferative neoplasms, megakaryocytes develop abnormally and contribute to key pathological features of the disease, including the harmful scarring that destroys the bone marrow.
I trained at Clare College, Cambridge, Imperial College London/The Hammersmith Hospital, Cornell, New York, and the National Institutes of Health, Bethesda USA and am currently a Cancer Research UK Advanced Clinician Scientist and Honorary Consultant in Haematology, Oxford University Hospitals NHS Trust. I am also a Senior Fellow of New College, Oxford.
Key publications
-
Journal article
Khan AO. et al, (2022), Cancer Discovery
-
Journal article
Psaila B. et al, (2020), Molecular Cell, 78, 477 - 492.e8
-
Journal article
Psaila B. et al, (2016), Genome Biology, 17
-
Journal article
Sousos N. et al, (2022), Nature Medicine, 28, 1207 - 1211
-
Journal article
Roy A. et al, (2021), Cell Reports, 36, 109698 - 109698
Recent publications
-
Journal article
Rodriguez-Meira A. et al, (2023), Nat Genet
-
Journal article
Ryou H. et al, (2023), Leukemia
-
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients
Journal article
HARRINGTON H. et al, (2022), Leukemia
-
Journal article
Ryou H. et al, (2022), Leukemia
-
Journal article
Khan AO. et al, (2022), Cancer Discovery
ORCID
0000-0001-8198-9663